Global Refractory Multiple Myeloma Global Clinical Trials Review 2014
M2 - 2 hrs 1 min ago
Research and Markets (http://www.researchandmarkets.com/research/gphksg/refractory) has announced the addition of the "Refractory Multiple Myeloma Global Clinical Trials Review, H1, 2014" report to their offering. Refractory Multiple Myeloma Global Clinical Trials Review, H1, 2014" provides data on the Refractory Multiple Myeloma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Refractory Multiple Myeloma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Refractory Multiple Myeloma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Profiles of Top Companies/Organisations - Celgene Corporation - Amgen Inc. - Johnson & Johnson - Takeda Pharmaceutical Company Limited - Novartis AG - Merck & Co., Inc. - F. Hoffmann-La Roche Ltd. - Pfizer Inc. - Bristol-Myers Squibb Company - AbbVie Inc. - National Cancer Institute - Fred Hutchinson Cancer Research Center - Mayo Clinic - The University of Texas M. D. Anderson Cancer Center - University of Arkansas - Case Comprehensive Cancer Center - Memorial Sloan Kettering Cancer Center - City of Hope National Medical Center - Washington University School of Medicinea For more information visit http://www.researchandmarkets.com/research/gphksg/refractory
Say Hello to 3 Existing and Upcoming Next-Generation Blockbuster Drugs
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 26, 12:26PM CDT
Investing in biopharmaceutical stocks can be an uphill battle from day one. For example, Medscape notes that of any 5,000 to 10,000 drugs investigated in a preclinical setting, only one will make it to pharmacy shelves . That's an extremely high...
Hepatitis C Space Heats Up
Brian Orelli, The Motley Fool - Motley Fool - Fri Apr 25, 5:30PM CDT
What looked like a two-horse hepatitis C race between Gilead Sciences and AbbVie has gotten more interesting, with Merck and Bristol-Myers Squibb presenting data on their hepatitis C drugs at a scientific meeting earlier this month. ...
3 Questions About a Big Pharma Megamerger
Seth Robey, The Motley Fool - Motley Fool - Fri Apr 25, 1:30PM CDT
It's been hard to miss the action in Big Pharma this week, as some of the most established drug makers engaged in a series of acquisition, merger, and asset swap rumors. A buyout of English company AstraZeneca by American powerhouse Pfizer was...
Schedule for Upcoming Earnings Releases -- Research on Nokia, Boston Scientific, Merck & Co., and Bristol-Myers Squibb
PR Newswire - Fri Apr 25, 1:09PM CDT
Earningsource.com provides investors with earnings schedule updates throughout the earnings season. With timely information on past earnings performance and earnings projection for their upcoming quarterly release, our aim is to ensure shareholders and traders have an edge on their investment decisions on the following companies: Nokia OYJ (NYSE: NOK), Boston Scientific Corp. (NYSE: BSX), Merck & Co. Inc. (NYSE: MRK) and Bristol-Myers Squibb Co. (NYSE: BMY). Full earnings notes on NOK, BSX, MRK and BMY can be downloaded upon signing up at:
Midday Glance: Pharmaceuticals companies
AP - Fri Apr 25, 12:23PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Early Glance: Pharmaceuticals companies
AP - Fri Apr 25, 9:32AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
What You Should Know About Gilead's Sovaldi And Johnson & Johnson's Olysio
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 24, 5:30PM CDT
Over the past five years, few drugs have been as highly anticipated as Gilead's Sovaldi, a new-generation oral treatment for hepatitis C infection. Sovaldi won FDA approval in December, and despite only being available for a few weeks, Sovaldi...
Final Glance: Pharmaceuticals companies
AP - Thu Apr 24, 5:04PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Alexion Posts Strong Earnings in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 4:00PM CDT
Alexion (ALXN) handsomely beat the Zacks Consensus Estimate in the first quarter.
Bristol-Myers Squibb Ranks First on 2014 Best Corporate Citizens List
Business Wire - Thu Apr 24, 12:01PM CDT
Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has been ranked No. 1 on Corporate Responsibility magazine's 2014 list of the 100 Best Corporate Citizens, a leading benchmark for socially responsible investors and other stakeholders.
The Medicines Co.'s Q1 Earnings Surpass Expectations - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 10:40AM CDT
The Medicines Co. (MDCO) also announced an acquisition agreement which reflects its efforts to diversify its portfolio and reduce its dependence on Angiomax.
Is This Struggling Drugmaker Worth $100 Billion?
Dan Carroll, The Motley Fool - Motley Fool - Thu Apr 24, 8:30AM CDT
The pharmaceutical world got a shock this week from reports that Pfizer had engaged in informal talks with Big Pharma rival AstraZeneca about a possible $100 billion acquisition. AstraZeneca reportedly expressed no interest in the...
The Zacks Analyst Blog Highlights
PR Newswire - Thu Apr 24, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Pandora Media, Inc. (NYSE
AstraZeneca's Q1 Profit Falls 11% Despite Strong Diabetes Drug Growth
Sean Williams, The Motley Fool - Motley Fool - Thu Apr 24, 7:36AM CDT
Just days after rumors swirled about a possible takeover offer, global pharmaceutical giant AstraZeneca reported its first-quarter results very early this morning, delivering modest top-line growth but seeing its profits shrink notably. For...
Allied Minds Names Peter Dolan and Jeff Rohr to Board of Directors
Business Wire - Thu Apr 24, 7:03AM CDT
Allied Minds, a dedicated technology commercialization firm that develops businesses and products based on innovative technologies developed at US universities and federal research institutions, today announced the appointment of Peter Dolan and Jeff Rohr as new members of its Board of Directors, effectively immediately.
Quarterly Results, FDA Approvals, Intellectual Property Appeals, New Drug Applications, and Initiated Clinical Trials - Analyst Notes on Johnson & Johnson, Merck, Teva, Bristol-Myers Squibb and AbbVie
PR Newswire - Thu Apr 24, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Bristol-Myers Squibb Company (NYSE: BMY) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1516-100free.
Will These 3 Dividend Stocks Impress Investors This Earnings Season?
Dan Carroll, The Motley Fool - Motley Fool - Wed Apr 23, 5:30PM CDT
Earnings season already has produced its fair share of surprises, but big pharma's hardly even broken out of the gate so far. However, a trio of major drugmakers are set to release their quarterly results in the next two weeks, and all eyes in the...